Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enphase Energy
ENPH
|
+$433M |
| 2 |
Coupang
CPNG
|
+$426M |
| 3 |
Meta Platforms (Facebook)
META
|
+$351M |
| 4 |
Sea Limited
SE
|
+$328M |
| 5 |
XYZ
Block Inc
XYZ
|
+$326M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mercado Libre
MELI
|
+$919M |
| 2 |
Tesla
TSLA
|
+$857M |
| 3 |
Illumina
ILMN
|
+$616M |
| 4 |
Trade Desk
TTD
|
+$273M |
| 5 |
Netflix
NFLX
|
+$211M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 29.23% |
| 2 | Technology | 27.33% |
| 3 | Healthcare | 14.71% |
| 4 | Communication Services | 12.31% |
| 5 | Financials | 6.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
Fortis
FTS
$28.7B
| $16.8M | 0.01% |
406,552
+376,947
| +1,273% | +$15.2M |
|
202
Charles River Laboratories
CRL
$12.8B
| $16.6M | 0.01% |
70,202
-9,370
| -12% | -$1.84M |
|
203
Ionis Pharmaceuticals
IONS
$9.4B
| $15.1M | 0.01% |
298,483
-18,146
| -6% | -$869K |
|
204
Booking.com
BKNG
$161B
| $14.2M | 0.01% |
99,850
-12,900
| -11% | -$1.61M |
|
205
Mine Safety
MSA
$7.49B
| $13.1M | 0.01% |
+77,747
| New | +$12.6M |
|
206
Sun Communities
SUI
$14.7B
| $12.9M | 0.01% |
+96,700
| New | +$11.6M |
|
207
Progressive
PGR
$125B
| $12.9M | 0.01% |
80,745
-34,006
| -30% | -$5.32M |
|
|
ADAP
208
DELISTED
Adaptimmune Therapeutics
ADAP
| $12.6M | 0.01% |
15,912,140
-1,235,269
| -7% | -$696K |
|
209
TJX Companies
TJX
$178B
| $12.4M | 0.01% |
132,582
-35,105
| -21% | -$3.15M |
|
210
Graco
GGG
$13.5B
| $12.4M | 0.01% |
+142,649
| New | +$11.2M |
|
211
Zillow
ZG
$7.63B
| $11.5M | 0.01% |
203,531
-98,455
| -33% | -$4.22M |
|
212
AutoZone
AZO
$51.1B
| $11.4M | 0.01% |
4,413
-723
| -14% | -$1.88M |
|
213
MongoDB
MDB
$32.1B
| $11.2M | 0.01% |
27,511
+21,559
| +362% | +$8.18M |
|
|
DCBO
214
Docebo
DCBO
$566M
| $11.2M | 0.01% |
230,561
-5,731
| -2% | -$255K |
|
215
EverQuote
EVER
$906M
| $11M | 0.01% |
897,234
-336,385
| -27% | -$3.06M |
|
216
Nike
NKE
$61.9B
| $10.9M | 0.01% |
100,756
+45,455
| +82% | +$4.88M |
|
217
CarMax
KMX
$8.26B
| $10.9M | 0.01% |
142,285
-17,230
| -11% | -$1.16M |
|
218
PayPal
PYPL
$50.5B
| $10.8M | 0.01% |
176,168
-21,795
| -11% | -$1.25M |
|
219
Codexis
CDXS
$158M
| $10.4M | 0.01% |
3,419,093
-630,474
| -16% | -$1.35M |
|
220
Veeva Systems
VEEV
$37.4B
| $10.4M | 0.01% |
54,035
-3,666
| -6% | -$691K |
|
221
ResMed
RMD
$30.7B
| $10.3M | 0.01% |
60,046
-3,498
| -6% | -$537K |
|
222
Ascendis Pharma A/S
ASND
$16.8B
| $10.3M | 0.01% |
81,670
-4,651
| -5% | -$464K |
|
223
Stratasys
SSYS
$774M
| $10.1M | 0.01% |
708,737
-118,456
| -14% | -$1.39M |
|
|
MASI
224
DELISTED
Masimo
MASI
| $10.1M | 0.01% |
86,188
-5,041
| -6% | -$470K |
|
225
Visa
V
$677B
| $10M | 0.01% |
38,548
-4,900
| -11% | -$1.21M |
|
Similar funds
Baillie Gifford & Co's Q4 2023 Portfolio in Review
As of Q4 2023, Baillie Gifford & Co held 303 positions worth $126B, up 15% from $110B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Baillie Gifford & Co's Q4 2023 filing shows 14 new, 69 increased, 196 reduced and 15 closed positions. Its largest new stake was Insulet: 1,212,759 shares worth $263M. The largest sale was Mercado Libre, an estimated $919M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 29% of assets, down from 30% a quarter earlier, followed by Technology and Healthcare.
- Baillie Gifford & Co's largest Q4 2023 buy was Insulet: 1,212,759 shares worth $263M.
- Baillie Gifford & Co added most to Enphase Energy in Q4 2023, an estimated $433M increase.
- Baillie Gifford & Co's biggest Q4 2023 reduction was Mercado Libre, cutting an estimated $919M.
- Baillie Gifford & Co fully exited Abcam PLC in Q4 2023, selling an estimated $165M.
- Baillie Gifford & Co's ten largest holdings make up 41% of its $126B portfolio in Q4 2023.
- Baillie Gifford & Co opened 14 new positions and closed 15 in Q4 2023.
- Baillie Gifford & Co's portfolio value rose 15% quarter-over-quarter to $126B.
Based on Baillie Gifford & Co's 13F filing for Q4 2023, filed 26 Jan 2024.